Evidence suggests that SGLT2 inhibition induces erythropoiesis, and in patients with T2DM, erythropoiesis levels were significantly increased after 1 month of treatment with empagliflozin (Mazer et al., 2020). Here, SLC5A2 is linked to type 2 diabetes mellitus.